MERS-CoV Nucleocapsid Alexa Fluor® 700-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: Nucleocapsid

MERS-CoV, which causes the Middles East Respiratory Syndrome (MERS), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelope, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (1, 2). The MERS-CoV N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an Intrinsically Disordered Region (3) and an RNA binding domain (4), the linker region interacts with the M protein and the C-terminal region contains a self-association domain (1, 2). The MERS-CoV N protein shares 46.3% and 4.5% amino acid sequence identity with SARS-CoV-1 and SARS-CoV-2 N protein, respectively. MERS-CoV N proteins have been shown to inhibit Type I Interferon(IFN) production(1). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity, making it a promising therapeutic target (5-7).

Product Datasheets

Related Research Areas

• Infectious Diseases